Stay updated on Pembrolizumab in MM Residual Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.

Latest updates to the Pembrolizumab in MM Residual Disease Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a new MedlinePlus Genetics topic: Multiple myeloma, expanding core genetics coverage with a specific medical condition.SummaryDifference0.2%

- Check20 days agoChange Detected- Added a government-operating-status notice and confirmation that the NIH Clinical Center is open, plus a version update to v3.2.0. - Removed a MedlinePlus Genetics topic: multiple myeloma (v3.1.0) from the topics.SummaryDifference3%

- Check27 days agoChange DetectedTerminology updated from Plasma cell myeloma to Multiple myeloma and version bumped from v3.0.2 to v3.1.0. The change mainly reflects standard naming and versioning; no other substantive content changes are indicated.SummaryDifference0.1%

- Check41 days agoChange DetectedUpdated to Revision: v3.0.2 and removed 'Back to Top'.SummaryDifference0.1%

- Check48 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%

- Check55 days agoChange DetectedThe web page has undergone significant changes, including the addition of specific facility names and locations related to plasma cell myeloma, while also removing previous mentions of multiple myeloma and related terms.SummaryDifference2%

Stay in the know with updates to Pembrolizumab in MM Residual Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.